Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1994-01-18
1998-07-07
Prior, Kimberly J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514172, 514173, 514178, 514179, 514180, 514181, A61K 3158, A61K 31565
Patent
active
057769230
ABSTRACT:
Sex steroid precursors such as dehydroepiandrosterone and dehydroepiandrosterone sulphate, and compounds converted in vivo to ether of the foregoing, are utilized for the treatment and/or prevention of vaginal atrophy, hyprogonadism, diminished libido, osteoporosis, urinary incontinence, ovarian cancer, uterine cancer, skin atrophy, for contraception, and, in combination with an estrogen and/or progestin, for the treatment of menopause. The precursors may be formulated for percutaneous or transmucosal administration. Gels, solutions, lotions, creams, ointments and transdermal patches for the administration of these precursors are provided, as are certain pharmaceutical compositions and kits which can be used for the prevention and treatment of a wide variety of conditions related to decreased secretion of sex steroid precursors by the adrenals.
REFERENCES:
patent: 3472931 (1969-10-01), Stoughton
patent: 3551554 (1970-12-01), Herschler
patent: 3742951 (1973-07-01), Zaffaroni
patent: 3797494 (1974-03-01), Zaffaroni
patent: 3989816 (1976-11-01), Jagannath
patent: 4006218 (1977-02-01), Tibor
patent: 4213978 (1980-07-01), Bodor
patent: 4405616 (1983-09-01), Rajadhyaksha
patent: 4425339 (1984-01-01), Pitchford
patent: 4496556 (1985-01-01), Orentreich
patent: 4518595 (1985-05-01), Coleman
patent: 4542129 (1985-09-01), Orentreich
patent: 4568343 (1986-02-01), Leeper
patent: 4624665 (1986-11-01), Nuwayser
patent: 4666441 (1987-05-01), Andriola
patent: 4812447 (1989-03-01), Roberts
patent: 4835147 (1989-05-01), Roberts
patent: 4956355 (1990-09-01), Prendergast
patent: 4978532 (1990-12-01), El-Rashidy
patent: 5047244 (1991-09-01), Sanvordeker et al.
patent: 5051260 (1991-09-01), Chess
patent: 5064654 (1991-11-01), Berner
patent: 5071644 (1991-12-01), Viegas
patent: 5071657 (1991-12-01), Oloff
patent: 5116828 (1992-05-01), Miura et al.
patent: 5135480 (1992-08-01), Bannon
patent: 5154922 (1992-10-01), Govil
patent: 5162037 (1992-11-01), Whitson
patent: 5362720 (1994-11-01), Labrie
The Merck Index, 9th Ed., 1976, p. 376, #2846.
Djerassi, et al., J. Org. Chem. 27:1112 (1962).
Ringold, et al., J. Am. Chem. Soc. 78:816 (1956).
Poulin et al., Br. Cancer Res. Treat. 13:265-276 (1989).
Wink, et al., Calcif. Tissue Int. 32:77-82 (1980).
Wittliff (1984) Cancer 53:630-643.
Yamashita, et al., Agric. Biol. Chem. 39:2243-2244 (1975).
Yen, et al., Lipids 12:409-413 (1977).
Zumoff, et al., J. Clin. Endocrinol. Metab. 54:534-538 (1982).
Mortola, et al., "The Effects of Oral Dehydroepiandrosterone on Endocrine-Metabolic Parameters in Postmenopausal Women", Journal of Clinical Endocrinology and Metabolism, vol. 71, No. 3 (1990).
Bird, et al., "Dehydroepiandrosterone Sulfate: Kinetics of Metabolism in Normal Young Men and Women", Clinical & Investigative Medicine, vol. 7, No. 2, pp. 119-122 (1984).
Roberts, et al., "Serum Steroid Levels i Two Old Men with Alzheimer's Disease (AD) Before, During, and After Oral Administration of Dehydroepiandrosterone (DHEA). Pregnenolone Synthesis May Become Rate-Limiting in Aging", The Biological Role of Dehydroepiandrosterone (DHEA) (1990).
Roberts, et al., "Oral Dehydroepiandrosterone in Multiple Sclerosis. Results of a Phase One, Open Study", The Biological Role of Dehydroepiandrosterone (DHEA) (1990).
Belisle, et al., "The Effect of Constant Infusion of Unlabeled Dehydroepiandrosterone Sulfate on Maternal Plasma Androgens and Estrogens", Journal of Clinical Endocrinology & Metabolism, vol. 45, No. 3 (1977).
Haning, Jr., et al., "Metabolic Clearance Rate (MCR) of Dehydroepiandrosterone Sulfate (DS), Its Metabolism to Dehydroepiandrosterone, Androstenedione, Testosterone, and Dihydrotestosterone, and the Effect of Increased Plasma DS Concentration on DS MCR in Normal women", Journal of Clinical Endocrinology & Metabolism, vol. 69, No. 5 (1989).
Abou-Gharbia M; Cheeseman EN; Pashko L; Schwartz A; Swern D (1984) Epiandrosterone-and dehydroepiandrosterone-3.beta.-alkanesulfonates as inhibitors of mouse glucose-6-phosphatase dehydrogenase activity. J. Pharm. Sci. 73: 1643-5.
Adams, J. B. (1985) Control of secretion and the function of C19-.DELTA.5-steroids of the human adrenal gland. Mol. Cell. Endocrinol. 41: 1-17.
Aloia, J. F.; Vaswanim, A. N.; Yed, J. K.; Ross, P., Ellis K.; Cohn, S. H. (1983) Determinants of bone mass in postmenopausal women. Arch. Int. Med. 143: 1700-1704.
Arad Y; Badimon JJ; Badimon L; Hembree WC; Ginsberg HN (1989) Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbit. Arteriosclerosis. 2: 159-166.
Baran, D. T.; Bergfeld, M. A.; Teitelbaum, S. L.; Avioli, L. W. (1978) Effect of testosterone therapy on bone formation in an osteoporotic hypogonadal male. Calcif. Tissue Res. 26: 103-106.
Barrett-Connor, E.; Khaw, K. T.; Yen, S. S. C. (1986) A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. New Engl. J. Med. 315: 1519-1524.
Belanger A; Labrie F (1990) Unconjugated and glucuronide steroid levels in human breast cyst fluid. In: Biochemistry of breast cyst fluid. Correlation with breast cancer risk (A Angeli, HL Bradlow, FI Chasalow, L Dogliotti, eds), New York: Annals of the New York Academy of Sciences. 586: pp. 93-100.
Brownsey, B.; Cameron, E. H. D.; Griffiths, K.; Gleave, E. N.; Forrest, A. P. M.; Campbell, H. (1972) Plasma dehydreopiandrosterone sulphate levels in patients with benign and malignant breast disease. Europ. J. Cancer. 8: 131-137.
Bulbrook RD; Hayward JL; Spicer CC; Thomas BS (1962) Abnormal excretion of urinary steroids by women with early breast cancer. The Lancet. Dec.: 1238-1240.
Bulbrook RD; Hayard JL; Spicer CC; Thomas CS (1962) A comparison between the urinary steroid excretion of normal women and women with advanced breast cancer. The Lancet. Dec.: 1235-1240.
Bulbrook RD; Hayward JL; Spicer CC (1971) Relation between urinary androgen and corticoid excretion and subsequent breast cancer. The Lancet. Aug.:395-398.
Bundgaard H (1991) Design and application of prodrugs. In: A textbook of drug design and development (P. Krogsgaard-Larsen, H. Bundgaard, eds), Harwood Academic Publishers GmfH, Chur:Switzerland. pp. 113-191.
Buster JE; Casson PR; Straughn AR; Dale D; Umstot ES; Chiamori N; Abraham GE (1992) Postmenopausal steroid replacement with micronized dehydroepiandrosterone:preliminary oral bioavailability and dose proportionality studies. Am. J. Obstet. Gynecol. 166: 1163-1170.
Cameron EHD; Griffiths K; Gleave EN; Stewart HJ; Forrest APM; Campbell H (1970) Benign and malignant breast disease in south wales: a study or urinary steroids. Br. Med. J. 4:768-771.
Challis JRG; Heap RB (1970) Steroid mono-and diheptafluorobutyrates; preparation, purification and estimation. J. Chromatogr. 50: 228-238.
Cleary MP; Zisk J (1983) Effect of dehydroepiandrosterone (DHEA) in adult zucker rats. Fed. Proc.42: 536 (abst. 1433).
Coleman, D. L.; Schwizer, R. W.; Lieter, E. H. (1983) Effect of genetic background on the therapeutic effects of dehydroepiandrosterone (DHEA) in diabetes-obesity mutants and in aged normal mice. Diabetes. 33: 26-33.
Colevard DS; Eriksen EF; Keeting PE; Wilson EM; Lubahn DB; French FS; Riggs BL; Spelesberg TC (1989) Identification of androgen receptors in normal human osteroblast-like cells. Proc. Natl. Acad. Sci. USA, 86: 854-857.
Dauvois S; Geng CS; Levesque C; Merand Y; Labrie F (1991) Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res. 54:3131-3135.
Deutsch, S.; Benjamin, F.; Seltzer, V.; Tafreshi, M.; Kocheril, G.; Frank, A. (1987) The correlation of serum estrogens and androgens with bone density in the late postmenopause. Int. J. Gynecol. Obstet. 25: 217-222.
Drefahl G (1982) Derivatisierung von dextran mit p-Amino-benzoesaure-androstenolonester. Z. Chem. 22: 178.
Drucker WD; Blumberg JM; Gandy HM; David RR; Verde AL (1972) Biologic activity of dehydroepiandrosterone sulfate in man. J. Clin. Endocrinol. Metab. 35: 48-54.
Druzgala et al. (1991) J. Steroid Biochem. Molec. Biol. 38: 149-154.
Edman CD
Endorecherche Inc.
Prior Kimberly J.
LandOfFree
Method of treating or preventing osteoporosis by adminstering de does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating or preventing osteoporosis by adminstering de, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating or preventing osteoporosis by adminstering de will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1206057